Sionna Therapeutics is trading 5.6% down now at $6.10, following the August 10 Phase 2a failure of SION-719.
- Sionna stopped advancing SION-719 as an add-on to standard care.
- No new company announcement directly explains the August 17, 2026 decline. Reuters reported the setback; shareholder-law-firm investigations were announced August 16.
- Broader indexes are modestly lower, but the move appears primarily stock-specific; the immediate catalyst remains uncertain.